285 related articles for article (PubMed ID: 34897704)
1. Melanoma trials that defined surgical management: Brief overview of current/upcoming adjuvant/neoadjuvant trials.
Patel A; Skitzki J
J Surg Oncol; 2022 Jan; 125(1):38-45. PubMed ID: 34897704
[TBL] [Abstract][Full Text] [Related]
2. Targeting BRAF and MEK inhibitors in melanoma in the metastatic, neoadjuvant and adjuvant setting.
Tétu P; Baroudjian B; Lebbe C
Curr Opin Oncol; 2020 Mar; 32(2):85-90. PubMed ID: 31895121
[TBL] [Abstract][Full Text] [Related]
3. Systemic adjuvant therapy for adult patients at high risk for recurrent melanoma: A systematic review.
Baetz TD; Fletcher GG; Knight G; McWhirter E; Rajagopal S; Song X; Petrella TM
Cancer Treat Rev; 2020 Jul; 87():102032. PubMed ID: 32473511
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant therapy of malignant melanoma and the role of sentinel node mapping.
Eggermont AM
Recent Results Cancer Res; 2000; 157():178-89. PubMed ID: 10857171
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial.
Amaria RN; Prieto PA; Tetzlaff MT; Reuben A; Andrews MC; Ross MI; Glitza IC; Cormier J; Hwu WJ; Tawbi HA; Patel SP; Lee JE; Gershenwald JE; Spencer CN; Gopalakrishnan V; Bassett R; Simpson L; Mouton R; Hudgens CW; Zhao L; Zhu H; Cooper ZA; Wani K; Lazar A; Hwu P; Diab A; Wong MK; McQuade JL; Royal R; Lucci A; Burton EM; Reddy S; Sharma P; Allison J; Futreal PA; Woodman SE; Davies MA; Wargo JA
Lancet Oncol; 2018 Feb; 19(2):181-193. PubMed ID: 29361468
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant immunotherapy for melanoma.
Thomas D; Bello DM
J Surg Oncol; 2021 Mar; 123(3):789-797. PubMed ID: 33595889
[TBL] [Abstract][Full Text] [Related]
7. The 2017 complete overhaul of adjuvant therapies for high-risk melanoma and its consequences for staging and management of melanoma patients.
Eggermont AMM; Dummer R
Eur J Cancer; 2017 Nov; 86():101-105. PubMed ID: 28968566
[TBL] [Abstract][Full Text] [Related]
8. Considering adjuvant therapy for stage II melanoma.
Poklepovic AS; Luke JJ
Cancer; 2020 Mar; 126(6):1166-1174. PubMed ID: 31869447
[TBL] [Abstract][Full Text] [Related]
9. Management of adjuvant settings for Stage III melanoma patients in France prior to checkpoint inhibitors: epidemiological data from the RIC-Mel database.
Dalle S; Varey E; Nguyen JM; Dupuy A; Montaudie H; Lesage C; Mortier L; Leccia MT; Skowron F; Celerier P; Meyer N; Dutriaux C; Dalac-Rat S; Khammari A; Lebbe C; Dréno B
Eur J Dermatol; 2020 Aug; 30(4):389-396. PubMed ID: 32815816
[TBL] [Abstract][Full Text] [Related]
10. Treatment of High Risk Resected Melanoma in Australia: Current Landscape and Practises.
Bhave P; Haydon A
Australas J Dermatol; 2020 Aug; 61(3):203-209. PubMed ID: 32403192
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant immunotherapy of melanoma and development of new approaches using the neoadjuvant approach.
Davar D; Tarhini AA; Kirkwood JM
Clin Dermatol; 2013; 31(3):237-50. PubMed ID: 23608443
[TBL] [Abstract][Full Text] [Related]
12. Neo-DREAM study investigating Daromun for the treatment of clinical stage IIIB/C melanoma.
Miura JT; Zager JS
Future Oncol; 2019 Nov; 15(32):3665-3674. PubMed ID: 31538818
[TBL] [Abstract][Full Text] [Related]
13. Rapidly Evolving Pre- and Post-surgical Systemic Treatment of Melanoma.
Augustin RC; Luke JJ
Am J Clin Dermatol; 2024 May; 25(3):421-434. PubMed ID: 38409643
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant Therapy for Melanoma.
Lowe MC; Kudchadkar RR
Surg Oncol Clin N Am; 2020 Jul; 29(3):445-453. PubMed ID: 32482319
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant Checkpoint Immunotherapy and Melanoma: The Time Is Now.
Long GV; Menzies AM; Scolyer RA
J Clin Oncol; 2023 Jun; 41(17):3236-3248. PubMed ID: 37104746
[TBL] [Abstract][Full Text] [Related]
16. Malignant melanoma: non-metastatic.
Crosby D; Crosby T; Mason M
Clin Evid; 2002 Jun; (7):1519-29. PubMed ID: 12230768
[No Abstract] [Full Text] [Related]
17. First line treatment of BRAF mutated advanced melanoma: Does one size fit all?
Giugliano F; Crimini E; Tarantino P; Zagami P; Uliano J; Corti C; Trapani D; Curigliano G; Ascierto PA
Cancer Treat Rev; 2021 Sep; 99():102253. PubMed ID: 34186441
[TBL] [Abstract][Full Text] [Related]
18. Surgical approach to patients with low-burden stage III melanoma: Is it time to consider conservative surgery?
Moreno-Ramírez D; Vieira R; Kaufmann R
Eur J Surg Oncol; 2020 Apr; 46(4 Pt A):498-500. PubMed ID: 31767498
[No Abstract] [Full Text] [Related]
19. Neoadjuvant Immunotherapy for Locally Advanced Melanoma.
Pelster MS; Amaria RN
Curr Treat Options Oncol; 2020 Feb; 21(2):10. PubMed ID: 32025932
[TBL] [Abstract][Full Text] [Related]
20. Immune Checkpoint Therapies for Melanoma.
Buchbinder EI
Hematol Oncol Clin North Am; 2021 Feb; 35(1):99-109. PubMed ID: 33759776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
